July 2019
Volume 60, Issue 9
Free
ARVO Annual Meeting Abstract  |   July 2019
A negative immune regulator SOCS3 controls laser-induced choroidal neovascularization
Author Affiliations & Notes
  • Ye Sun
    Ophthalmology, Boston Children's Hosp/Harvard Med Sch, Boston, Massachusetts, United States
  • Chi-Hsiu Liu
    Ophthalmology, Boston Children's Hosp/Harvard Med Sch, Boston, Massachusetts, United States
  • Yan Gong
    Ophthalmology, Boston Children's Hosp/Harvard Med Sch, Boston, Massachusetts, United States
  • Bertan Cakir
    Ophthalmology, Boston Children's Hosp/Harvard Med Sch, Boston, Massachusetts, United States
  • Steve Cho
    Ophthalmology, Boston Children's Hosp/Harvard Med Sch, Boston, Massachusetts, United States
  • Alexander Poblete
    Ophthalmology, Boston Children's Hosp/Harvard Med Sch, Boston, Massachusetts, United States
  • William Britton
    Ophthalmology, Boston Children's Hosp/Harvard Med Sch, Boston, Massachusetts, United States
  • James D Akula
    Ophthalmology, Boston Children's Hosp/Harvard Med Sch, Boston, Massachusetts, United States
  • Jing Chen
    Ophthalmology, Boston Children's Hosp/Harvard Med Sch, Boston, Massachusetts, United States
  • Lois E H Smith
    Ophthalmology, Boston Children's Hosp/Harvard Med Sch, Boston, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Ye Sun, None; Chi-Hsiu Liu, None; Yan Gong, None; Bertan Cakir, None; Steve Cho, None; Alexander Poblete, None; William Britton, None; James Akula, None; Jing Chen, None; Lois Smith, None
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 2989. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ye Sun, Chi-Hsiu Liu, Yan Gong, Bertan Cakir, Steve Cho, Alexander Poblete, William Britton, James D Akula, Jing Chen, Lois E H Smith; A negative immune regulator SOCS3 controls laser-induced choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 2019;60(9):2989.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Choroidal neovascularization (CNV) is the major cause of vision loss in neovascular age-related macular degeneration (AMD). Immune dysregulation has been linked with CNV clinically and experimentally, specifically, immune cells of myeloid origin are attracted to and control experimental CNV, but the underlying mechanisms are largely unknown. We identified a novel factor, suppressor of cytokine signaling 3 (SOCS3), that controls CNV through modulating inflammatory mediators, immune cell activation and infiltrationin myeloid cells.

Methods : We generated SOCS3 knock-out and knock-in mice using the Cre/loxP system. Myeloid specific Cre mice as well as mT/mG Cre reporter mice were used in laser-induced CNV mouse models of pathological NV. Real-time PCR, western blot and immunohistochemistry were used to analyze gene expression and protein localization. Confocal imaging, fundus fluorescein angiography and HE staining were used to identify phenotypes. FACS was used for immune cell population assay and immune cell isolation. NV was quantified using image J. Results are presented as mean ± SEM and were compared using the 2-tailed unpaired t-test. Statistical analyses were performed with GraphPad Prism (v6.0).

Results : In the laser CNV mouse model, myeloid specific deletion of SOCS3 increased CNV by 30-40% (p<0.001, n=26-30), and myeloid specific overexpression of SOCS3 reduced CNV by ~25% (p<0.001, n=30). These data suggested that myeloid specific SOCS3 controls pathological NV in a laser-CNV model. Pharmacologic treatment with a SOCS3 activator suppressed CNV by 40% in the laser CNV model (p<0.001, n=45-50).

Conclusions : These findings suggested that overexpression of SOCS3 in myeloid cells suppressed CNV by controlling inflammatory mediators which control immune cell activation and infiltration.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×